ArticleMolecular carcinogenesis2020

The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies.

Mahamat Babagana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.